Icotinib(BPI-2009H)
610798-31-7
2026-07-01
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName Icotinib(BPI-2009H) Cat No CEI-0911 Description Icotinib is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). Phase 4. Alias BPI-2009H CAS No 610798-31-7 Molecular Weight 391.42 Storage 2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO. Synonyms BPI-2009H Targets EGFR IC50 5 nM Molecular Formula C22H21N3O4 Chemical Name [1,4,7,10]Tetraoxacyclododecino[2,3-g]quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro- Solubility DMSO 78 mg/mL; Water <1 mg/mL; Ethanol 7 mg/mL In vitro Icotinib inhibits EGFR activity in a dose-dependent manner, with an IC50 value of 5 nM and complete inhibition at 62.5 nM. Icotinib selectively solely inhibits the EGFR members including the wild type and mutants with inhibition efficacies of 61-99%. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation in human epidermoid carcinoma A431 cells in a dose-dependent manner. Meanwhile, in our proliferation assay performed on A431, BGC-823, A549, H460, HCT8, KB and Bel-7402 cell lines, we found that the relative sensitivity of cell lines to Icotinib is A431 > BGC-823 > A549 > H460 > KB > HCT8 and Bel-7402. Icotinib exhibits a broad spectrum of antitumor activity and it is especially effective against tumors expressing higher levels of EGFR. In vivo Icotinib shows an antitumor effect in different types of xenografts. Icotinib inhibits tumor growth at a rate of 51.5%, 31.0% and 67.4% in the A431, A549 and H460 xenografts at a dose of 120 mg/kg, respectively. category Inhibitors(c1514) cas_num 610798-31-7 Basic Info-
Product Name:
Icotinib
Other Name:[1,4,7,10]Tetraoxacyclododecino[2,3-g]quinazolin-4-amine,N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-;N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine;Icotinib;BPI 2009H;1640118-92-8
CAS No.:610798-31-7
Molecular Formula:C22H21N3O4
InChIKeys:InChIKey=QQLKULDARVNMAL-UHFFFAOYSA-N
Molecular Weight:391.43
Exact Mass:391.42
EC Number:1592732-453-0
UNII:9G6U5L461Q
DSSTox ID:DTXSID20209952
NCI Thesaurus Code:C138996
ATC Code:L - Antineoplastic and immunomodulating agents
HScode:29339900
Categories:
Characteristics-
PSA:
74.7
XLogP3:3.1
Density:1.3±0.1 g/cm3
Boiling Point:581℃
Flash Point:305℃
Refractive Index:1.649
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product